208 related articles for article (PubMed ID: 33205481)
1. Histopathologic study of paradoxical psoriasis induced by antitumor necrosis factor alpha therapy: Is it true psoriasis?
Navarro R; Villar-Zarra K; Juarez Á; Daudén E
J Cutan Pathol; 2021 Jun; 48(6):813-816. PubMed ID: 33205481
[No Abstract] [Full Text] [Related]
2. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: A population-based cohort study.
Bae JM; Kwon HS; Kim GM; Park KS; Kim KJ
J Allergy Clin Immunol; 2018 Sep; 142(3):1001-1003.e2. PubMed ID: 29859201
[No Abstract] [Full Text] [Related]
4. Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy.
Boggs JME; Ramsay B; Lynch M
Clin Exp Dermatol; 2021 Apr; 46(3):580-582. PubMed ID: 33151572
[No Abstract] [Full Text] [Related]
5. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Groth D; Perez M; Treat JR; Castelo-Soccio L; Nativ S; Weiss PF; Lapidus S; Perman MJ
Pediatr Dermatol; 2019 Sep; 36(5):613-617. PubMed ID: 31240749
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
7. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
Sridhar S; Maltz RM; Boyle B; Kim SC
Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
[TBL] [Abstract][Full Text] [Related]
9. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
[TBL] [Abstract][Full Text] [Related]
10. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
11. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
Peer FC; Miller A; Pavli P; Subramaniam K
Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNFα antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease: an Irish Cohort Study.
Kirthi Jeyarajah S; Tobin AM; Hussey M; Scaldaferri F; McNamara D
QJM; 2017 Jun; 110(6):379-382. PubMed ID: 28069913
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.
Vasconcellos JB; Pereira DD; Vargas TJ; Levy RA; Pinheiro GD; Cursi ÍB
An Bras Dermatol; 2016; 91(5 suppl 1):137-139. PubMed ID: 28300922
[TBL] [Abstract][Full Text] [Related]
15. Systemic sarcoidosis reactions as a result of tumour necrosis factor-alpha treatment for patients with psoriasis.
Bewley AP; Maleki S
Clin Exp Dermatol; 2021 Dec; 46(8):1548-1550. PubMed ID: 34021925
[TBL] [Abstract][Full Text] [Related]
16. TNF-α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
Watabe D; Amano H
Eur J Dermatol; 2021 Jun; 31(3):412-413. PubMed ID: 34309528
[No Abstract] [Full Text] [Related]
17. [Paradoxical psoriasis induced by anti-TNF - a clinical challenge].
Nidegger A; Mylonas A; Conrad C
Rev Med Suisse; 2019 Mar; 15(644):668-671. PubMed ID: 30916904
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical reactions induced by tumor necrosis factor-alpha antagonists: A literature review based on 46 cases.
Olteanu R; Zota A
Indian J Dermatol Venereol Leprol; 2016; 82(1):7-12. PubMed ID: 26728803
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical psoriasis after exposure to tumour necrosis factor inhibitors in children: a retrospective cohort study.
Kodama S; Gupta D; Sullivan E; Rosenwasser N; Zhao Y
Br J Dermatol; 2022 Jun; 186(6):1043-1045. PubMed ID: 34993955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
